Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial by Panaccione, R, Colombel, J, Travis, S, Bossuyt, P, Baert, F, Vaňásek, T, Danalıoğlu, A, Novacek, G, Armuzzi, A, Reinisch, W, Johnson, S, Buessing, M, Neimark, E, Petersson, J, Lee, W, D'Haens, G

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. by Colombel, J, Panaccione, R, Bossuyt, P, Lukas, M, Baert, F, Vanasek, T, Danalioglu, A, Novacek, G, Armuzzi, A, Hébuterne, X, Travis, S, Danese, S, Reinisch, W, Sandborn, W, Rutgeerts, P, Hommes, D, Schreiber, S, Neimark, E, Huang, B, Zhou, Q, Mendez, P, Petersson, J, Wallace, K, Robinson, A, Thakkar, R, D'Haens, G

Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM by Yzet, C, Ungaro, R, Bossuyt, P, Baert, F, Vanasek, T, D'Haens, G, Joustra, V, Panaccione, R, Novacek, G, Armuzzi, A, Golovchenko, O, Prymak, O, Goldis, A, Travis, S, Hebuterne, X, Ferrante, M, Rogler, G, Fumery, M, Danese, S, Rydzewska, G, Pariente, B, Hertervig, E, Stanciu, C, Grimaud, J, Diculescu, M, Peyrin-Biroulet, L, Laharie, D, Wright, J, Gomollon, F, Gubonina, I, Schreiber, S, Motoya, S, Hellstrom, P, Halfvarson, J, Colombel, J